22 unknown. 22 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Unknown 22 |
| Phase 1 | 2 | Unknown 2 |
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B) - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 145 | 2023-05-15 | 2023-05-18 |
| Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer Pyrotinib, trastuzumab, paclitaxel-albumin - Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 65 | 2022-11-29 | 2024-04-16 |
| INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer INT230-6, Saline injection - Breast Cancer | Phase 2 | Unknown | Ottawa Hospital Research Institute | 90 | 2021-03-25 | 2021-11-17 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer Toripalimab, Paclitaxel/cisplatin, Intensity-modulated radiotherapy - Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Resectable Esophageal Cancer | Phase 2 | Unknown | Jianhua Fu | 44 | 2019-06-25 | 2019-12-26 |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Pomalidomide - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 18 | 2018-09-01 | 2018-11-14 |
| Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma Pembrolizumab - Kaposi Sarcoma, Progression, Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 17 | 2018-07-01 | 2019-10-21 |
| A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML Decitabine and Ara-C, Ara-C - Leukemia, Myeloid | Phase 2 | Unknown | Xuejie Jiang | 100 | 2018-02-01 | 2020-04-27 |
| Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma SRT to the resection cavity - Glioblastoma | Phase 2 | Unknown | Technical University of Munich | 162 | 2016-02-01 | 2020-03-10 |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib Afatinib - Triple Negative Breast Cancer | Phase 2 | Unknown | National Taiwan University Hospital | 40 | 2015-08-01 | 2016-04-15 |
| A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy steroid & Cyclosporin - Idiopathic Membranous Nephropathy, Proteinuria | Phase 2 | Unknown | Sun Yat-sen University | 180 | 2014-06-01 | 2014-07-01 |
| Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer carboplatin and paclitaxel and or without trastuzumab - Breast Cancer | Phase 2 | Unknown | Guangdong Provincial People's Hospital | 60 | 2013-11-01 | 2014-02-12 |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer Nab-Paclitaxel - Breast Cancer | Phase 2 | Unknown | Barwon Health | 60 | 2013-04-01 | 2017-07-02 |
| CNDO-109-AANK for AML in First Complete Remission (CR1) CNDO-109-AANK Cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Coronado Biosciences, Inc. | 12 | 2012-12-01 | 2017-06-29 |
| Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer Metformin - Locally Advanced Malignant Neoplasm | Phase 2 | Unknown | Instituto Nacional de Cancerologia de Mexico | 60 | 2012-04-01 | 2012-03-30 |
| MSC Administration for the Management of Type 1 Diabetic Patients MSCs - Type 1 Diabetes Mellitus | Phase 2 | Unknown | Universidad del Desarrollo | 10 | 2012-03-01 | 2016-09-08 |
| Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters LaborPro device - Pregnancy, Labor | Phase 2 | Unknown | Trig Medical Inc | 650 | 2009-03-01 | 2010-01-05 |
| Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients Hydroxychloroquine, Placebo - HIV Infections | Phase 2 | Unknown | Medical Research Council | 83 | 2008-06-01 | 2010-07-30 |
| Idiotypic Vaccination for Follicular Lymphoma Patients Follicular lymphoma, patient-specific, soluble protein idiotype vaccine - Follicular Lymphoma, First Relapse/Progression | Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 100 | 2007-10-01 | 2011-10-06 |
| Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma Sodium selenite (Introselen), Sodium selenite - Malignant Tumor, Treatment Resistant Disorders | Phase 1 / Phase 2 | Unknown | Karolinska University Hospital | 32 | 2007-02-01 | 2013-10-10 |
Showing 20 of 22. Sign in to see all of them.
Pathologic Complete Response (10) · Breast Neoplasms (6) · HIV Infections (2) · Leukemia, Myeloid, Acute (2) · Triple Negative Breast Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Diabetes Mellitus, Type 1 (1) · Esophageal Squamous Cell Carcinoma (1) · Fasting (1) · Glioblastoma (1) · Glomerulonephritis, Membranous (1) · Inflammation (1) · Insulin Resistance (1) · Leukemia, Myeloid (1)
Disease Attributes (22) · Pathologic Processes (22) · Pathological Conditions, Signs and Symptoms (22) · Neoplasms (14) · Neoplasms by Site (8) · Immune System Diseases (7) · Neoplasms by Histologic Type (7) · Breast Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Hemic and Lymphatic Diseases (4) · Urogenital Diseases (4) · Autoimmune Diseases (3) · Genital Diseases (3)
Trastuzumab (2) · 130-nm albumin-bound paclitaxel (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Carnitine (1) · Cisplatin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Cytarabine (1) · Decitabine (1) · Dexamethasone (1) · Esophagectomy (1) · Hydroxychloroquine (1) · Interferon beta-1a (1)
Assistance Publique - Hôpitaux de Paris (1) · Barwon Health (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Coronado Biosciences, Inc. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Gilead Sciences (1) · Guangdong Provincial People's Hospital (1) · Instituto Nacional de Cancerologia de Mexico (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · Jianhua Fu (1) · Karolinska University Hospital (1) · Medical Research Council (1) · Multiple Sclerosis Institute (1) · National Taiwan University Hospital (1) · Northwestern University (1)
China (5) · United States (5) · Mexico (2) · Australia (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Spain (1) · Sweden (1) · Taiwan (1)
Alberto Zambelli, MD (1) · Andrea Botticelli, MD (1) · Angel Arnaout, MD (1) · Arif Awan, MD (1) · Carla Strina, MD (1) · Chiun-Sheng Huang, PhD (1) · Claudia Arce, MD, MSc (1) · Claudio Mizon, MD (1) · Jeffrey I Greenstein, MD (1) · Jianhua Fu, MD (1) · Kun Wang, MD (1) · Maha H Hussain, M.D. (1) · Maria Vittoria Dieci, MD (1)
PMID 19299237, PMID 24529560, PMID 25092775, PMID 27872127, PMID 28317872, PMID 28869790, PMID 29298660, PMID 30642373, PMID 30763338, PMID 32101663, PMID 32120420, PMID 32393788, PMID 32669709, PMID 32848145, PMID 32966830, PMID 33181091, PMID 33278935, PMID 34731655, PMID 34778952, PMID 34789537, PMID 34861375, PMID 35279271, PMID 35810555, PMID 36210299, PMID 37560259, PMID 39235488
2016 (1), P30CA060553 (1)